Marinus Pharmaceuticals Inc. (NASDAQ: MRNS) shares are -0.46% down in the year-to-date (YTD) period and have moved -11.16% or -$0.24 lower in the latest trading session. However, stock’s trailing 12-month performance remains nearly +83.65% lower. Comparatively, the stock is -45.43% down YTD and -29.74% over the trailing 3-month period. If we look at the shorter duration, its week performance is 20.11% and 19.44% over the month.
On July 01, 2020, Cowen recommended the MRNS stock is a Outperform, while earlier, H.C. Wainwright had Reiterated the stock as a Buy on July 01, 2020. 9 analysts offering the recommendations for the stock have a consensus rating of 1.40 to suggest that the MRNS stock is a “Strong Buy. 0 of the 9 analysts rate the stock as a “Sell”, while 0 has rated it as “Underweight”. 8 recommend buying, with 1 rating it as an Overweight.
The stock currently trades at $1.91. The forecasts give the Marinus Pharmaceuticals Inc. stock a price target range of $9.00 on the higher side while at least one analyst think the stock could plunge to a low of $4.00. The two limits represent an upside potential of 78.78% or 52.25%.
Analysts estimate the earnings to increase 15.80% in the current quarter to -$0.17, up from the -$0.26 reported in the same quarter a year ago. Analysts also offered guidance for the next financial quarter, with their average projected EPS at between -$0.23 and -$0.02. Wall Street estimates earnings per share to be at an average of -$0.56 for the next year.
Insider Transactions Summary
According to SEC data, total insider shares purchases at the company stands at 1 over the last 12 months, while SEC filings reveal that there have been 1 insider sales over the same period. Insiders have purchases 100,000 shares while those sold by company executives and officers stand at 2,380. The last 3 months have seen insiders trade a total of 0 and 0 in purchases and sales respectively.
Braunstein Scott, a Chief Executive Officer at the company, bought 100,000 shares worth $0.13 million at $1.25 per share on Dec 13. The CFO had earlier sold another 2,380 MRNS shares valued at $4879.0 on Jan 30. The shares were sold at $2.05 per share.
PDS Biotechnology Corporation (NASDAQ:PDSB), on the other hand, is trading around $2.77 with a market cap of $62.30M and analyst research firms have a negative stance on its shares. Some analysts are even forecasting -$1.09 per share in earnings this year on a short term (1 year) basis.
Let us briefly look at the PDS Biotechnology Corporation (PDSB) financials, with a focus on its operating details as indicated in its earnings report for the last quarter.
Company balance sheet and cash flow
PDSB’s operating expenses over the recent quarter were at $7000.0. This represented a 99.76% of the company’s total revenues which amounted $2.94 million. With this in place, we can see that the company’s diluted EPS declined -$0.19 on the year-over-year period, shrinking to -$0.75 as given in the last earnings report.
In terms of the balance sheet & cash flow as of (Sep 2020), the total assets figure advanced to $20.09 million from $23.93 million over the previous quarter. The company’s free cash flow for the quarter was -$7.27 million.
Insiders have transacted a total of 0 times at PDS Biotechnology Corporation over the last 6 months, with insider purchases undertaken 0 times and accounting for 0 shares. Insider sales totaled 0 shares over the same period, with these deals completed in 0 transactions. Looking at these numbers, we realize that net purchases over that period are 0.0 shares. Insiders now hold a total of 5.52M shares after the latest sales, with 0.00% net shares purchased.
Insiders own 35.92% of the company shares, while shares held by institutions stand at 8.00% with a share float percentage of 10.75M. Investors are also buoyed by the number of investors in a company, with PDS Biotechnology Corporation having a total of 28 institutions that hold shares in the company. The top two institutional holders are Renaissance Technologies, LLC with over 0.62 million shares worth more than $1.25 million. As of Jun 29, 2020, Renaissance Technologies, LLC held 4.05% of shares outstanding.
The other major institutional holder is Federated Hermes, Inc., with the investment firm holding over 0.38 million shares as of Jun 29, 2020. The firm’s total holdings are worth over $0.77 million and represent 2.50% of shares outstanding.